Angiotension II receptor 1 blocker modifies the expression of apoptosis-related proteins and transforming growth factor-β1 in prostate tissue of spontaneously hypertensive rats

BJU International

Volumn 100, Issue 5, 2007, Pages 1161-1165

  Yu, Wei ^a   Zhao, Ya Yuan ^a   Zhang, Zhi Wen ^b   Guo, Ying Lu ^a   Jin, Jie ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b PEKING UNIVERSITY   (China)

Author keywords

Apoptosis; Prostate; Rat model; Rats; TGF 1; Type 1 angiotensin receptor blockers

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; APOPTOSIS REGULATORY PROTEIN; CASPASE 3; LOSARTAN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; ENZYME ACTIVITY; HISTOLOGY; HYPERTENSION; LOW DRUG DOSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROSTATE; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; PROSTATE VENTRAL LOBE; PROTEIN EXPRESSION; RAT; STIMULATION; WESTERN BLOTTING; WISTAR KYOTO RAT;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; LOSARTAN; MALE; PROSTATE; PROSTATIC HYPERPLASIA; RATS; RATS, INBRED SHR; RATS, INBRED WKY; TRANSFORMING GROWTH FACTOR BETA1;

EID: 35148817546     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.07150.x     Document Type: Article

References (30)

1. Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet 1991 338 : 469 71
2. Madsen FA, Bruskewitz RC. Benign prostatic hyperplasia. pathophysiology and pharmacological treatment. Curr Opin Nephrol Hypertens 1995 4 : 455 9
3. Turkes A, Griffiths K. In Kirby RS, McConnell JD, Fitzpatrick JM, Roehrborn CG, Boyle P eds, Textbook of Benign Prostatic Hyperplasia, 2nd edn. Chapt 3, London : Taylor & Francis, 2005 : 29 68
4. Michel MC, Heemann U, Schumacher H, Mehlburger L, Goepel M. Association of hypertension with symptoms of benign prostatic hyperplasia. J Urol 2004 172 : 1390 3
5. Fabiani ME. Angiotensin receptor subtypes: novel targets for cardiovascular therapy. Drug News Perspect 1999 12 : 207 15
6. Dinh DT, Frauman AG, Sourial M, Casley DJ, Johnston CI, Fabiani ME. Identification, distribution, and expression of angiotensin II receptors in the normal human prostate and benign prostatic hyperplasia. Endocrinology 2001 142 : 1349 56
7. Unger T. The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol 2002 89 : 3 9
8. Matsubara H, Inada M. Molecular insights into angiotensin II type 1 and type 2 receptors: expression, signaling and physiological function and clinical application of its antagonists. Endocrinol J 1998 45 : 137 50
9. Chung O, Kuhl H, Stoll M, Unger T. Physiological and pharmacological implication of AT1 versus AT2 receptors. Kidney Int 1998 67 (Suppl. 95 9
10. Dinh DT, Frauman AG, Somers GR et al. Evidence for activation of the renin-angiotensin system in the human prostate: increased angiotensin II and reduced AT (1) receptor expression in benign prostatic hyperplasia. J Pathol 2002 196 : 213 9
11. Untergasser G, Madersbacher S, Berger P. Benign prostatic hyperplasia: age-related tissue-remodeling. Exp Gerontol 2005 40 : 121 8
12. Ueki M, Koda M, Yamamoto S, Matsunaga Y, Murawaki Y. Preventive and therapeutic effects of angiotensin II type 1 receptor blocker on hepatic fibrosis induced by bile duct ligation in rats. J Gastroenterol 2006 41 : 996 1004
13. Bobik A. Hypertension, transforming growth factor-beta, angiotensin II and kidney disease. J Hypertens 2004 22 : 1265 7
14. Lujan M, Ferruelo A, Paez A, Moreno A, Berenguer A. Prostate apoptosis after doxazosin treatment in the spontaneous hypertensive rat model. BJU Int 2004 93 : 410 4
15. Howard CV, Reed NG. Unbiased stereology. Three-dimensional measurement. In : Microscopy. Oxford, UK. BIOS, 1998 : 55 68
16. Simbulan-Rosenthal CM, Rosenthal DS, Iyer S, Boulares AH, Smulson ME. Transient poly (ADP-ribosyl) ation of nuclear proteins and role of poly (ADP-ribose) polymerase in the early stages of apoptosis. J Biol Chem 1998 273 : 13703 12
17. Furukawa S, Yamamoto O, Tamura T et al. Influence of efonidipine hydrochloride, calcium antagonist on the epithelium of prostates in spontaneously hypertensive rats. J Toxicol Sci 1994 19 : 213 7
18. Uemura H, Ishiguro H, Nakaigawa N et al. Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells. a possibility of tyrosine kinase inhibitor of growth factor. Mol Cancer Ther 2003 2 : 1139 47
19. Uemura H, Hasumi H, Ishiguro H, Teranishi J, Miyoshi Y, Kubota Y. Renin-angiotensin system is an important factor in hormone refractory prostate cancer. Prostate 2006 66 : 822 30
20. Uemura H, Hasumi H, Kawahara T et al. Pilot study of angiotensin II receptor blocker in advanced hormone-refractory prostate cancer. Int J Clin Oncol 2005 10 : 405 10
21. Pawlikowski M, Melen-Mucha G, Mucha S. The involvement of angiotensins in the control of prostatic epithelial cell proliferation in the rat. Folia Histochem Cytobiol 2001 39 : 341 3
22. Brady HJ, Gil-Gomez G. Bax. The pro-apoptotic Bcl-2 family member, Bax. Int J Biochem Cell Biol 1998 30 : 647 50
23. Lee C, Sintich SM, Mathews EP et al. Transforming growth factor-beta in benign and malignant prostate. Prostate 1999 39 : 285 90
24. Glassman DT, Chon JK, Borkowski A, Jacobs SC, Kyprianou N. Combined effect of terazosin and finasteride on apoptosis, cell proliferation, and transforming growth factor-beta expression in benign prostatic hyperplasia. Prostate 2001 46 : 45 51
25. Wikstrom P, Westin P, Stattin P, Damber JE, Bergh A. Early castration-induced upregulation of transforming growth factor beta1 and its receptors is associated with tumor cell apoptosis and a major decline in serum prostate-specific antigen in prostate cancer patients. Prostate 1999 38 : 268 77
26. Ahmed MM, Alcock RA, Chendil D et al. Restoration of transforming growth factor-beta signaling enhances radiosensitivity by altering the Bcl-2/Bax ratio in the p53 mutant pancreatic cancer cell line MIA PaCa-2. J Biol Chem 2002 277 : 2234 46
27. Di Paolo S, Schena A, Stallone G et al. Captopril enhances transforming growth factor (TGF)-beta1 expression in peripheral blood mononuclear cells: a mechanism independent from angiotensin converting enzyme inhibition? A study in cyclosporine-treated kidney-transplanted patients. Transplantation 2002 74 : 1710 5
28. Uemura H, Ishiguro H, Nagashima Y et al. Antiproliferative activity of angiotensin II receptor blocker through cross-talk between stromal and epithelial prostate cancer cells. Mol Cancer Ther 2005 4 : 1699 709
29. Schroder D, Heger J, Piper HM, Euler G. Angiotensin II stimulates apoptosis via TGF-beta1 signaling in ventricular cardiomyocytes of rat. J Mol Med 2006 84 : 975 83
30. Chatterjee PK, Weerackody RP, Mistry SK, Hawksworth GM, McLay JS. Selective antagonism of the AT1 receptor inhibits angiotensin II stimulated DNA and protein synthesis in primary cultures of human proximal tubular cells. Kidney Int 1997 52 : 699 705